£810 / $1295 / €985
Pharmaceutical companies will continue to look to fast growing emerging markets for revenue growth, and we believe that Latin American economies, with rising incomes, ageing populations and increased spending on healthcare will provide significant opportunities. Indeed, it is our view that emerging markets will be the main drivers of the pharmaceutical sector's expansion over the coming years as growth in traditional markets such as the US, Western Europe and Japan remains lacklustre. We note however, that imported patented and high-cost drugs, mostly originating from Europe and the US, account for a significant portion of the Latin American pharmaceutical market in terms of value.
Headline Expenditure Projections
Pharmaceuticals: CLP1,508bn (US$3.12bn) in 2011 to CLP1,642bn (US$3.22bn) in 2012; +8.9% in local currency terms and +3.3% in US dollar terms.
Healthcare: CLP9,034bn (US$18.67bn) in 2011 to CLP9,941bn (US$19.49bn) in 2012; +10.0% in local currency terms and +4.4% in US dollar terms.
Medical devices: CLP256.33bn (US$530mn) in 2011 to CLP267.45bn (US$525mn) in 2012; +4.3% in local currency terms and -1.0% in US dollar terms.
Risk/Reward Rating: In Q4 12's America's pharmaceutical risk / reward ratings (RRRs) matrix, Chile ranks in seventh place out of the 17 countries surveyed, scoring a total of 53.7 out of 100. We expect Chile, which has a favourable rewards profile, to climb up the regional matrix over the coming years as operational risks become addressed. In the Q412 RRRs, with regards to the country's attractiveness to innovative drug companies, Chile stands above Argentina and Peru and below Mexico and Brazil.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.